OncLive® On Air

In today’s episode, we welcomed Noa Biran, MD, to discuss some of the key multiple myeloma data to emerge from the 2026 ASCO Annual Meeting. Dr Biran is the medical director of Clinical Protocol Data Management and an associate professor of medicine in the Multiple Myeloma Division at Hackensack Meridian Health and John Theurer Cancer Center in New Jersey.
In the exclusive interview, Dr Biran detailed key data from pivotal studies such as the phase 3 MajesTEC-9 (NCT05572515) and SUCCESSOR-2 (NCT05552976) trials, and explained how emerging data could affect the multiple myeloma treatment landscape.

In this episode of Oncology Unplugged, host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Petros Grivas, MD, PhD, FASCO, the medical director of local/regional outreach and international program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, as well as a professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.
Their discussion centered on key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding landscape of perioperative, metastatic, and non–muscle-invasive disease management. Drs Park and Grivas first addressed findings from the phase 3 VOLGA trial (NCT04960709), which evaluated neoadjuvant durvalumab (Imfinzi) plus enfortumab vedotin-ejfv (Padcev), with or without tremelimumab (Imjudo), followed by cystectomy and adjuvant durvalumab in patients with cisplatin-ineligible or cisplatin-declining muscle-invasive bladder cancer. Dr Grivas noted that the durvalumab/enfortumab vedotin arm met both event-free survival (EFS) and overall survival (OS) end points, whereas the tremelimumab arm met the end point for EFS but not OS. He emphasized that the need for adjuvant enfortumab vedotin remains an open question.
The conversation then turned to the discordant results among trials in cisplatin-eligible patients. Dr Grivas contrasted the positive phase 3 NIAGARA trial (NCT03732677) data with the results of the phase 3 KEYNOTE-866 (NCT03924856) and ENERGIZE (NCT03661320) trials, which did not meet their EFS end points, and noted that all 3 enfortumab vedotin–based perioperative trials were positive. They also discussed exploratory circulating tumor DNA analyses from VOLGA and the phase 3 KEYNOTE-B15 study (NCT04700124), molecular subtype analysis findings from NIAGARA, and ongoing bladder-preservation trials.
Drs Park and Grivas also reviewed data in metastatic disease, including from cohort 7 of the phase 2 TROPHY-U-01 trial (NCT03547973), in which sacituzumab govitecan-hziy (Trodelvy) plus enfortumab vedotin and zimberelimab (AB122/GLS-010) yielded a high overall response rate. They also discussed data with sacituzumab tirumotecan (MK-2870/SKB264) plus pembrolizumab (Keytruda). In non–muscle-invasive disease, Dr Grivas discussed data from the phase 3 POTOMAC trial (NCT03528694) of durvalumab plus BCG and the role of shared decision-making in bladder cancer management. The experts concluded by highlighting developments in artificial intelligence, as well as the importance of patient advocacy and clinical trial participation.

In our exclusive interview, Dr Haddad discussed the importance of consistent daily adherence to oral TKIs for achieving deep responses, treatment-free remission, and long-term survival in patients with CML. Additionally, he broke down common barriers to TKI adherence, including busy schedules, travel, and under-recognized adverse effects (AEs), underscoring the use of dose reductions and therapy changes to manage AEs and keep patients on treatment. Finally, Haddad explored where liquid and orally disintegrating TKI formulations, such as imatinib oral solution (Imkeldi), may help patients who cannot swallow, those with advanced-phase CML or Philadelphia chromosome–positive acute lymphoblastic leukemia, and pediatric patients.

In today’s episode, we spoke with Nathan A. Boggs, MD, PhD, about the role the allergists play in the diagnosis and management of systemic mastocytosis. Dr Boggs is the director of the Allergy Division in the School of Medicine of Uniformed Services University of the Health Sciences in Bethesda, Maryland.
In our exclusive interview, Dr Boggs broke down how allergists/immunologists fit into the multidisciplinary diagnosis and treatment of patients with systemic mastocytosis. Additionally, Boggs highlighted key strategies for symptom management and how agents such as avapritinib (Ayvakit), bezuclastinib (CGT9486), and elenestinib (BLU-263) have and will continue to affect the treatment paradigm.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.
In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a board exam preparation guide for the days leading up to the American Board of Internal Medicine hematology and oncology certification exams, offering test-day strategies and a rapid-fire review of high-yield topics.
The discussion began with exam logistics, noting back-to-back testing days on November 17 (hematology) and November 18 (oncology). Drs Armstrong and Tawagi encouraged examinees to use the exam blueprint to prioritize high-yield topics, such as gastrointestinal, breast, genitourinary, and lung cancers in oncology and neoplasms in hematology, and to prepare for the endurance required to read lengthy clinical vignettes.
Regarding oncology content, they reviewed topics to know regarding stage II and III non–small cell lung cancer, including staging, perioperative immunotherapy regimens, driver-directed adjuvant therapy, and the clinical implications of the phase 3 PACIFIC trial (NCT02125461). They then covered high-yield breast cancer topics, such as HER2-positive regimens, the 21-gene recurrence score assay cutoffs, triple-negative adjuvant strategies, and use of PARP inhibitors in patients with BRCA mutations.
For hematology, they emphasized the malignant hematologic conditions, hemoglobin electrophoresis, von Willebrand disease subtypes, and inherited bone marrow failure syndromes, including dyskeratosis congenita, Fanconi anemia, and Diamond-Blackfan anemia.
Drs Armstrong and Tawagi also highlighted other testable areas, including black box warnings, clinical research methodology, ethics, performance status–guided decision-making, and supportive care. They concluded with wellness advice, cautioning against last-minute cramming, and recommended revisiting their prior board review episodes.